Bottles of antiretroviral drug Truvada. Photo: Justin Sullivan/Getty Images

The Justice Department is reviewing the government patent for use of an HIV prevention drug, potentially signaling that it's considering action against the drugmaker that sells it, the Washington Post reports.

The bottom line: The drug, Truvada, is owned by Gilead, which sells it for between $1,600 and 2,000 a month.

Details: A retired Centers for Disease Control scientist told the Post that a Justice Department lawyer visited the CDC last month to talk to government scientists who discovered Truvada's preventative use.

  • Gilead says the government's patent is invalid.

Why it matters: Truvada is key to the administration's goal of eradicating HIV by 2030, as it helps prevent new infections. But its price tag is creating patient access issues.

"We are in discussions with the government to determine the best ways to broaden access to Truvada for PrEP to vulnerable populations in the United States and support the federal plan to end the HIV epidemic."
— Gilead's statement to the Post

The big picture: It's rare for the government to sue for drug patent infringement, although the Department of Health and Human Services has patented more than 2,500 products since 1976, WashPost reported last month.

  • These discoveries were publicly financed, but the government often licenses them to private drug companies, which commercialize them.

Go deeper: Big Pharma's GOP firewall is weakening

Go deeper

Felix Salmon, author of Capital
Updated 28 mins ago - Economy & Business

Trump risk rises for companies

Illustration: Aïda Amer/Axios

Donald Trump fancies himself a businessman — and has given himself a central role in determining the conduct and even the existence of major companies both domestic and foreign.

Why it matters: America has historically been a great place to operate a company under the rule of law, and not be beholden to political whim. Those days seem to be over — at least for companies in the communications industry.

Ben Geman, author of Generate
Updated 28 mins ago - Energy & Environment

China's split personality on climate

Illustration: Sarah Grillo/Axios

A new insta-analysis of China's vow to achieve "carbon neutrality" before 2060 helps to underscore why Tuesday's announcement sent shockwaves through the climate and energy world.

Why it matters: Per the Climate Action Tracker, a research group, following through would lower projected global warming 0.2 to 0.3°C. That's a lot!

Kayleigh McEnany: Trump will accept "free and fair" election, no answer on if he loses

White House press secretary Kayleigh McEnany said Thursday that President Trump will "accept the results of a free and fair election," but did not specify whether he will commit to a peaceful transfer of power if he loses to Joe Biden.

Why it matters: Trump refused to say on Wednesday whether he would commit to a peaceful transition of power, instead remarking: "we're going to have to see what happens."

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!